PDCD1 and hypertensive disorder: Two patients (1.0%) were determined to have died from donafenib- and PD-1 inhibitor–related AEs, including one case of hepatic encephalopathy from donafenib and camrelizumab and one case of cerebral hemorrhage because of hypertension from donafenib and toripalimab.